COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02388906
Recruitment Status : Active, not recruiting
First Posted : March 17, 2015
Last Update Posted : November 13, 2019
Ono Pharmaceutical Co. Ltd
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.

Condition or disease Intervention/treatment Phase
Melanoma Drug: Ipilimumab Drug: Nivolumab Other: Placebo matching Ipilimumab Other: Placebo matching Nivolumab Phase 3

Detailed Description:
Italy, Greece, and Argentina: ≥ 18 years of age

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1264 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
Actual Study Start Date : March 12, 2015
Actual Primary Completion Date : November 26, 2018
Estimated Study Completion Date : November 26, 2019

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Ipilimumab and Placebo matching Nivolumab
Ipilimumab IV infusion and Placebo as specified
Drug: Ipilimumab
Other: Placebo matching Nivolumab
Experimental: Nivolumab and Placebo matching Ipilimumab
Nivolumab IV infusion and Placebo as specified
Drug: Nivolumab
Other: Placebo matching Ipilimumab

Primary Outcome Measures :
  1. Recurrence -free-survival [ Time Frame: Upto 36 months ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Upto 48 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects < 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ≥ 18 years of age
  • Completely removed melanoma by surgery performed within 12 weeks of randomization
  • Stage IIIb/C or Stage IV before complete resection
  • No previous anti-cancer treatment

Exclusion Criteria:

  • Ocular or uveal melanoma
  • History of carcinomatosis meningitis
  • History of auto-immune disease
  • Treatment directed against the resected melanoma that is administrated after the surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02388906

Show Show 136 study locations
Sponsors and Collaborators
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT02388906    
Other Study ID Numbers: CA209-238
2014-002351-26 ( EudraCT Number )
First Posted: March 17, 2015    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Disease Attributes
Pathologic Processes
Antineoplastic Agents, Immunological
Antineoplastic Agents